Posted: 3 October
Aculeus Therapeutics is a life sciences company focused on discovering and developing novel immunotherapies to treat a range of serious diseases. Today, Aculeus announced that it has initiated Investigational New Drug, or IND-enabling, studies for its lead program, STING. Aculeus has selected its preclinical development candidate, ACU-0943, which activates the STING (stimulator of interferon genes) pathway to boost immune responses to cancer.
The Company expects to begin formal GLP (good laboratory practice) toxicology studies in the first quarter of 2023. Aculeus is already in communication with the FDA and is planning to submit a Pre-IND meeting request ahead of the Phase 1 start. If ACU-0943 moves successfully through IND-enabling studies, as expected, the Company plans to conduct a multi-centre phase 1a/1b study in Australia commencing in the first half of 2024.
